State Street SPDR Portfolio S&P 500 ETF (SPYM) recorded a net outflow of $110.3 million on Thursday, Oct. 29, with gross activity of $116.9 million. The fund added to 19 positions and reduced 479 across its 502-stock portfolio, a broad trimming pattern. Its largest purchases were Fair Isaac (FICO), Assurant (AIZ) and A.O. Smith (AOS), each at $0.3 million, while the biggest sales were NVIDIA ($8.6 million), Apple ($8.5 million) and Microsoft ($6.6 million). No new positions were opened and no holdings were fully exited.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Open a keyword to see other news on the same topic.
Related news
- Does Paul Tudor Jones Know Something Wall Street Doesn't? The Billionaire Says It's 1999 All Over and That 2027 Is Going to Be 'Really, Really Challenging' for the Market.
Billionaire Paul Tudor Jones, who founded Tudor Investment in 1980, says the market resembles 1999 on the eve of the dot-com bust and that 2027 will be 'really, really challenging' for stocks. His main concern is investment flows: after subtracting IPOs, secondary offerings and IPO lock-up expirations, he sees the most negative U.S. stock flow picture since 2002, as the corporate support from buybacks and M&A has shifted. He also flags AI safety as a risk that could weigh on valuations. The S&P 500 is around 7,800, and strategists' price targets include 8,700 from Goldman Sachs, 9,000 from Jefferies and 8,800 from Fundstrat's Tom Lee. Jones expects a possible bounce after the midterms but a tougher 2027, while the article says long-term retail investors can ride out volatility and holders of many individual AI stocks should review valuations and risks.
- iShares Core S&P 500 (IVV) Sells $45 Million of NVIDIA on Oct. 29
The iShares Core S&P 500 ETF (IVV), with $870.02 billion in assets, sold $573.2 million of stock on Thursday and made no purchases. It decreased 495 positions and increased none. Its largest sales were NVDA ($45.0 million, 210,765 shares), AAPL ($44.3 million) and MSFT ($34.3 million), while Amazon.com Inc shed $20.8 million and Alphabet Class A $14.5 million. None of the sales were new positions or full exits, and no buys were reported.
- From Uptober to Hacktober: Are Bitcoin’s seasonal patterns becoming obsolete?
Bitcoin fell 7.3% in October 2026, following a roughly 4% decline a year earlier, according to CoinGlass data, defying the month’s historically bullish “Uptober” reputation. Amid a wave of crypto security incidents, including Binance’s record $6.3 billion hack, industry figures turned to labels such as “Black October” and “Hacktober.” Andrew Yang of Kaiko noted that October has posted Bitcoin’s highest median return at 15.4% and gains in 10 of 13 years through 2025, while Bitcoin’s typical monthly move has shrunk from 14% in 2013–2016 to 9.6% since 2024. Analysts such as Justin d’Anethan of Arctic Digital said ETF flows and corporate buyers are shaped more by liquidity, interest rates and investment mandates than by seasonal narratives, and US spot Bitcoin ETFs recorded $515 million in net outflows in October. Other analysts caution that two losses do not settle the question, as October has generally performed better in bull markets.
- JPMorgan Global Select Equity ETF (JGLO) Adds Microsoft and NXP on Oct. 29
JPMorgan Global Select Equity ETF (JGLO) made 10 position additions and 7 reductions on Thursday, with gross activity of $122.6 million against $6.19 billion in assets. The fund was a net seller of $33.0 million, as sales of Alphabet ($22.0 million) and Apple ($21.0 million) outweighed its largest purchase, Microsoft ($18.9 million). Other notable buys included NXP Semiconductors ($6.6 million) and Meta Platforms ($6.4 million), while Taiwan Semiconductor ($16.2 million) was among the trimmed holdings. No positions were newly opened or fully exited.
- Spdr Dow Jones Industrial Avg ETF (DIA) Adds Goldman Sachs and Caterpillar on Thursday
Spdr Dow Jones Industrial Average ETF Trust (DIA) recorded net buying of $130.6 million on Thursday, with no shares sold, and increased all 30 of its positions without decreasing any. Within its $45.14 billion portfolio, the largest buys were Goldman Sachs Group ($13.8 million, lifting its weight to 10.53%), Caterpillar ($9.6 million) and Microsoft ($7.9 million). Amgen ($6.8 million) and UnitedHealth Group ($6.1 million) also drew buying. None of the purchases were new positions and there were no sellouts.
- What iShares Russell 1000 Value ETF (IWD) Bought: Apple Leads on Thursday
iShares Russell 1000 Value ETF (IWD) was the only ETF buying on Thursday, with no ETFs selling, recording $140.6 million in gross trades that were all net buying. The fund increased 849 positions and decreased none, with assets under management of $83.22 billion. Its largest purchases were Apple ($8.7 million), Amazon.com ($8.1 million) and Microsoft ($7.4 million), followed by Berkshire Hathaway Class B ($3.8 million) and JPMorgan Chase ($3.5 million). None of the largest buys were new positions, and there were no sellouts.
Related markets
Latest news
- In the hunt for $1 trillion of revenue, SpaceX reportedly targets Boost Mobile for a deal
The article says there has been intense speculation about SpaceX's ambitions in the cellular market, with multiple acquisition targets suggested. Boost Mobile is the latest of these.
- Gold prices today, Monday, November 2, 2026: Gold opens at its lowest point in over a year ahead of midterms
Gold December futures opened at $3,890 per troy ounce on Monday, down 0.2% from Friday's close, and rose slightly to $3,913.70 by 7:02 a.m. ET. The opening price was the lowest since October 3, 2025, as a sharp equities selloff led investors to sell gold to raise cash, according to Dana Samuelson of American Gold Exchange. He said the gold market was already weak and vulnerable, trading just above its major July support of $3,975, and its break below that level worsened the decline. Compared with a week, a month and a year earlier, the opening price was down 3%, 7.5% and 3.7%, respectively.
- Marvell Plunges 13% on Lumentum Takeover Rumors: Make Your 3-5 Year Bet Right Now
Marvell (MRVL) shares fell 14.05% over the past week to $196.40 after reports of a possible takeover of Lumentum (LITE), and Marvell has issued no official statement. Lumentum's market cap is about $76.2 billion versus about $172.2 billion for Marvell, and the article says a deal would be a heavy lift, possibly requiring new stock or debt on top of $4.96 billion in existing debt. Marvell raised its fiscal 2027 revenue outlook to roughly $12 billion and fiscal 2028 to about $18 billion, and the stock trades at 26x forward earnings. Of 46 analysts covering the stock, 8 rate it Strong Buy, 32 Buy, 6 Hold and none Sell, with a consensus target of $340.56 implying 73.4% upside. Risks cited include reliance on a few hyperscalers and a beta of 2.26, and the fiscal third-quarter report, measured against guidance of $3.15 billion revenue and $1.10 non-GAAP EPS, is the next checkpoint.
- AWS Holds the Scale Crown, Azure Leads the Velocity Charge
AWS and Azure both posted record quarters but are growing in different ways. AWS revenue reached $45.98 billion, up 39%, its sixth straight quarter of faster growth, with a 38.7% operating margin. Azure grew 48%, daily Copilot users rose over 5x, and CFO Amy Hood forecast 49% to 50% constant-currency Azure growth next quarter. Amazon designs its own Trainium chips and plans to sell them outside AWS in late 2027, while Microsoft Cloud gross margin slipped to 66%. Microsoft generated $18.6 billion of free cash flow, while Amazon's trailing free cash outflow reached $42.4 billion.
- Tech stocks enter November after a brutal October: Is it time to buy the dip?
According to the article, both stock and bond markets are raising doubts about whether the AI trade can be sustained after a difficult October for tech stocks.
- Should You Invest $1,000 in BridgeBio Pharma Right Now?
BridgeBio Pharma (BBIO) focuses on rare genetic diseases and has two approved therapies, Attruby and Nulibry, with Attruby accounting for 71% of third-quarter revenue. The article lists three upcoming FDA milestones: a PDUFA date of Nov. 27 for BBP-418, Feb. 4 for oral infigratinib and May 8 for encaleret. Third-quarter total revenue reached $353.2 million, up 193% year over year, including $253.2 million of U.S. net product revenue for Attruby, while the EPS loss narrowed to $0.42 from $0.95. The company reported more than $1.5 billion in cash, nearly 3 times the year-ago level, after closing a $1 billion preferred equity financing. The article acknowledges risks tied to small patient populations but presents three reasons to consider the stock.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.